Seaport Therapeutics Inc has appointed Sharon Mates to its board of directors. Dr Mates was co-founder, chair and chief executive officer of Intra-Cellular Therapies from its inception in 2002 to its acquisition by Johnson & Johnson in 2025. With decades of experience in neuropsychiatry, she will help to support Seaport’s development of treatments for depression, anxiety and other neuropsychiatric disorders. During Dr Mates’ leadership, Intra-Cellular Therapies developed medicines for mental health disorders including bipolar disorder, depression and schizophrenia, and received US Food and Drug Administration approval for its antipsychotic Caplyta.
She is currently on the boards of Medincell and Benitec. Dr Mates has a BS from Ohio State University, a PhD from the University of Washington, and completed postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School.
Seaport Therapeutics announced the appointment on 27 April 2026.
Copyright 2026 Evernow Publishing Ltd.